{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:27:16Z","timestamp":1765546036306,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.eplepsyres.2015.09.011","type":"journal-article","created":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T10:58:45Z","timestamp":1442833125000},"page":"5-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Do HLA-A markers predict skin-reactions from aromatic antiepileptic drugs in a Norwegian population? A case control study"],"prefix":"10.1016","volume":"118","author":[{"given":"Maryam","family":"Shirzadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ketil","family":"Thorstensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grethe","family":"Helde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torolf","family":"Moen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eylert","family":"Brodtkorb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0005","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/j.1528-1167.2007.01109.x","article-title":"Rash from antiepileptic drugs: influence by gender, age, and learning disability","volume":"48","author":"Alvestad","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0010","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.eplepsyres.2008.04.003","article-title":"Cross-reactivity pattern of rash from current aromatic antiepileptic drugs","volume":"80","author":"Alvestad","year":"2008","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0015","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/clpt.2013.55","article-title":"HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children","volume":"94","author":"Amstutz","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0020","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/epi.12564","article-title":"Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions","volume":"55","author":"Amstutz","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0025","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2217\/pgs.14.65","article-title":"Pharmacogenetics of antiepileptic drug-induced hypersensitivity","volume":"15","author":"Bloch","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0030","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.2217\/pgs.14.135","article-title":"HLA-A*02:01:01\/-B*35:01:01\/-C*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients","volume":"15","author":"Fricke-Galindo","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0035","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/FPC.0000000000000021","article-title":"HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis","volume":"24","author":"Grover","year":"2014","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0040","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1212\/01.wnl.0000334295.50403.4c","article-title":"Cross-sensitivity of skin rashes with antiepileptic drug use","volume":"71","author":"Hirsch","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0045","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0050","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eplepsyres.2013.05.004","article-title":"Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese","volume":"106","author":"Li","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0055","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0060","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2217\/pgs.11.165","article-title":"Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions","volume":"13","author":"McCormack","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"Suppl 3","key":"10.1016\/j.eplepsyres.2015.09.011_bib0065","first-page":"202","article-title":"Association between HLA-A*2402 allele and lamotrigine-induced Stevens\u2013Johnson syndrome in Han Chinese (P 640, 30th International Epilepsy Congress, Montreal, Canada, 23\u201327 June, 2013)","volume":"54","author":"Min","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0070","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0075","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in the Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0080","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaip.2013.11.005","article-title":"Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy","volume":"2","author":"Pavlos","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000335613","article-title":"Genetics and the potential for predictive tests in adverse drug reactions","volume":"97","author":"Pirmohamed","year":"2012","journal-title":"Chem. Immunol. Allergy"},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0090","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/clpt.2011.79","article-title":"Phenotype standardization for immune-mediated drug-induced skin injury","volume":"89","author":"Pirmohamed","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0095","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1600-0404.2011.01553.x","article-title":"Comparison of carbamazepine rash in multiple sclerosis and epilepsy","volume":"125","author":"Shirzadi","year":"2012","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0100","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3109\/00365513.2014.921835","article-title":"Carbamazepine-induced cutaneous reactions: a simple assay to identify patients carrying the HLA-A*31:01 allele","volume":"74","author":"Thorstensen","year":"2014","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0105","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.clineuro.2012.01.019","article-title":"Antiepileptic drug-induced skin reactions: a retrospective study and analysis in 3793 Chinese patients with epilepsy","volume":"114","author":"Wang","year":"2012","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0110","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.eplepsyres.2014.03.017","article-title":"Genetic susceptibility to the cross-reactivity of aromatic antiepileptic drugs-induced cutaneous adverse reactions","volume":"108","author":"Wang","year":"2014","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2015.09.011_bib0115","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/ijd.12570","article-title":"Association of HLA-B*1502 allele with lamotrigine-induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in Han Chinese subjects: a meta-analysis","volume":"54","author":"Zeng","year":"2015","journal-title":"Int. J. Dermatol."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092012111530053X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092012111530053X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:33:30Z","timestamp":1760276010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092012111530053X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":23,"alternative-id":["S092012111530053X"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.09.011","relation":{},"ISSN":["0920-1211"],"issn-type":[{"type":"print","value":"0920-1211"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do HLA-A markers predict skin-reactions from aromatic antiepileptic drugs in a Norwegian population? A case control study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}